ES2951817T3 - Derivados de imidazoquinolina de cadena alquílica modificada como agonistas de TLR7/8 y usos de los mismos - Google Patents

Derivados de imidazoquinolina de cadena alquílica modificada como agonistas de TLR7/8 y usos de los mismos Download PDF

Info

Publication number
ES2951817T3
ES2951817T3 ES18773000T ES18773000T ES2951817T3 ES 2951817 T3 ES2951817 T3 ES 2951817T3 ES 18773000 T ES18773000 T ES 18773000T ES 18773000 T ES18773000 T ES 18773000T ES 2951817 T3 ES2951817 T3 ES 2951817T3
Authority
ES
Spain
Prior art keywords
compound
methyl
compounds
alkyl
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18773000T
Other languages
English (en)
Spanish (es)
Inventor
Stewart D Chipman
John Demattei
Radwan Kiwan
Melissa A Kachura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynavax Technologies Corp
Original Assignee
Dynavax Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Technologies Corp filed Critical Dynavax Technologies Corp
Application granted granted Critical
Publication of ES2951817T3 publication Critical patent/ES2951817T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
ES18773000T 2017-08-22 2018-08-21 Derivados de imidazoquinolina de cadena alquílica modificada como agonistas de TLR7/8 y usos de los mismos Active ES2951817T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762548848P 2017-08-22 2017-08-22
PCT/US2018/047323 WO2019040491A1 (en) 2017-08-22 2018-08-21 MODIFIED ALKYL CHAIN IMIDAZOQUINOLINE TLR7 / 8 AGONIST COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
ES2951817T3 true ES2951817T3 (es) 2023-10-25

Family

ID=63638354

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18773000T Active ES2951817T3 (es) 2017-08-22 2018-08-21 Derivados de imidazoquinolina de cadena alquílica modificada como agonistas de TLR7/8 y usos de los mismos

Country Status (5)

Country Link
US (4) US10618896B2 (cg-RX-API-DMAC7.html)
EP (2) EP4257198A3 (cg-RX-API-DMAC7.html)
JP (3) JP7386536B2 (cg-RX-API-DMAC7.html)
ES (1) ES2951817T3 (cg-RX-API-DMAC7.html)
WO (1) WO2019040491A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4257198A3 (en) * 2017-08-22 2023-10-18 Dynavax Technologies Corporation Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof
US10722591B2 (en) 2017-11-14 2020-07-28 Dynavax Technologies Corporation Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
BR112021015577A2 (pt) 2019-02-08 2021-10-05 Research & Business Foundation Sungkyunkwan University Complexo-colesterol agonista do receptor toll-like 7 ou 8 e uso do mesmo
BR112022008039A2 (pt) 2019-10-29 2022-07-12 Prime Reach Trading Ltd Compostos de 4-amino-imidazoquinolina e usos relacionados
CN115666637A (zh) 2020-03-02 2023-01-31 蛋白科技先锋 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法
EP4146204A4 (en) * 2020-05-05 2024-07-03 Virovax LLC Vaccine adjuvants
EP4194008A4 (en) 2020-08-04 2025-01-08 Progeneer Inc. Kinetically acting adjuvant ensemble
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
CN113967256B (zh) * 2021-10-26 2022-09-30 山东大学 一种具有光热-化疗-免疫功能的纳米粒及其制备方法和应用
US20250025447A1 (en) * 2021-11-03 2025-01-23 Regents Of The University Of Minnesota Toll-like receptor agonists and antagonists and uses thereof
WO2023086890A1 (en) * 2021-11-10 2023-05-19 The University Of Chicago Small molecule immunopotentiator conjugates of nfkb activators as adjuvants with enhanced efficacy and reduced toxicity
CN116731015B (zh) * 2023-05-18 2024-09-27 深圳威科森生物医药科技有限公司 咪唑并喹啉化合物及其制备方法、应用和组合物
EP4731632A1 (en) * 2023-06-21 2026-04-29 The Trustees of The University of Pennsylvania Toll-like receptor (tlr) agonist lipidoid compounds, lipid nanoparticles (lnps) comprising the same, and methods of use thereof
WO2025110816A1 (ko) 2023-11-23 2025-05-30 프로지니어 주식회사 암의 치료를 위한 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 항암 치료의 병용요법
WO2026046400A1 (zh) * 2024-08-30 2026-03-05 惠正奇生物技术(广州)有限公司 含杂芳环结构的脂质类化合物及其应用
CN119320387B (zh) * 2024-12-19 2025-06-27 杭州天龙药业有限公司 基于Toll样受体激动剂的疫苗佐剂脂质化合物及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
DK0708772T3 (da) 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo[4,5,-c]pyridin-4-aminer
JPH1180156A (ja) 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd 1−(置換アリール)アルキル−1h−イミダゾピリジン−4−アミン誘導体
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
HUP0201425A3 (en) 1999-04-23 2006-07-28 Hadasit Med Res Service Conjugate having a cleavable linkage for use in a liposome
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2004032829A2 (en) 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US6818650B2 (en) 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
JP2006513212A (ja) 2002-12-20 2006-04-20 スリーエム イノベイティブ プロパティズ カンパニー アリール/ヘタリール置換されたイミダゾキノリン
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Irm化合物およびトル様受容体8に関する方法および組成物
AU2004229478B2 (en) 2003-04-10 2009-12-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
CA2535338C (en) 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
RU2006121646A (ru) 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы
EP1765348B1 (en) 2004-06-18 2016-08-03 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2007079086A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体(tlr)を介して作用するイミダゾキノリン
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
US9556167B2 (en) 2012-05-02 2017-01-31 Yale University TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
WO2014113634A1 (en) 2013-01-17 2014-07-24 University Of Kansas Toll-like receptor 2-agonistic lipopeptides, and method of making the same
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US10471139B2 (en) 2013-08-15 2019-11-12 The University Of Kansas Toll-like receptor agonists
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
EP3092256B1 (en) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Compounds and compositions for immunotherapy
SG11201608299TA (en) 2014-05-01 2016-11-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
GB201418004D0 (en) 2014-10-10 2014-11-26 Isis Innovation Polymer adjuvant
WO2017044803A1 (en) 2015-09-09 2017-03-16 The United States Of America, As Represented By The Secretary Department Of Health And Human Service Expression vector delivery system and use thereof for inducing an immune response
EP3356371A4 (en) 2015-09-29 2020-06-24 The University of Chicago POLYMER CONJUGATE VACCINE
CR20180229A (es) 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
WO2018112108A1 (en) 2016-12-13 2018-06-21 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
US10328895B2 (en) 2017-03-17 2019-06-25 Autoliv Asp, Inc. Seatbelt pretensioning retractor assembly including a pretensioner rod
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US20180311334A1 (en) 2017-04-29 2018-11-01 Yale University Compositions and Methods for Inducing an Immune Response
EP4257198A3 (en) 2017-08-22 2023-10-18 Dynavax Technologies Corporation Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof
BR112020004505A2 (pt) 2017-09-06 2020-09-15 BioNTech SE imidazoquinolinas substituídas como agonistas de tlr7
US10722591B2 (en) 2017-11-14 2020-07-28 Dynavax Technologies Corporation Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof

Also Published As

Publication number Publication date
US11124510B2 (en) 2021-09-21
US20240368155A1 (en) 2024-11-07
EP4257198A2 (en) 2023-10-11
JP2023129623A (ja) 2023-09-14
EP4257198A3 (en) 2023-10-18
US20190062329A1 (en) 2019-02-28
EP3672969B1 (en) 2023-07-05
EP3672969A1 (en) 2020-07-01
US11981670B2 (en) 2024-05-14
WO2019040491A1 (en) 2019-02-28
JP7386536B2 (ja) 2023-11-27
US10618896B2 (en) 2020-04-14
JP2020531530A (ja) 2020-11-05
JP2025131620A (ja) 2025-09-09
US20220033400A1 (en) 2022-02-03
US20200199124A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
US20240368155A1 (en) Alkyl chain modified imidazoquinoline tlr7/8 agonist compounds and uses thereof
JP6710727B2 (ja) 脂質付加された免疫反応調節化合物の組成物、製剤及び方法
CN108290845B (zh) 嘧啶化合物
US11833247B2 (en) Vaccine adjuvant formulation
KR102283760B1 (ko) 펩티드 접합된 입자
ES2389080T3 (es) Fármaco que presenta un ligando de células reguladoras contenido en el liposoma
CN114206378B (zh) 基于tlr受体配体的疫苗佐剂
Verma et al. CpG ODNs: Precision Immunotherapy and Recent Trends in Nano-Enabled Nucleotide Delivery
EA046871B1 (ru) Адъюванты вакцин на основе лигандов рецепторов tlr
JP2014122165A (ja) 免疫賦活剤
HK1217942B (en) Lipidated immune response modifier compound compositions, formulations, and methods